Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Sep 16;10(9):e0137680.
doi: 10.1371/journal.pone.0137680. eCollection 2015.

Levels of sP-selectin and hs-CRP Decrease With Dietary Intervention With Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

Affiliations
Free PMC article
Randomized Controlled Trial

Levels of sP-selectin and hs-CRP Decrease With Dietary Intervention With Selenium and Coenzyme Q10 Combined: A Secondary Analysis of a Randomized Clinical Trial

Urban Alehagen et al. PLoS One. .
Free PMC article

Abstract

Background/objectives: Inflammation and oxidative stress are central in many disease states. The major anti-oxidative enzymes contain selenium. The selenium intake in Europe is low, and supplementation with selenium and coenzyme Q10, important anti-oxidants, was evaluated in a previous study. The aim of this study was to evaluate response on the inflammatory biomarkers C-reactive protein, and sP-selectin, and their possible impact on cardiovascular mortality.

Subjects/methods: 437 elderly individuals were included in the study. Clinical examination, echocardiography, electrocardiography and blood samples were drawn. The intervention time was 48 months, and median follow-up was 5.2 years. The effects on inflammation/atherosclerosis were evaluated through analyses of CRP and sP-selectin. Evaluations of the effect of the intervention was performed using repeated measures of variance. All mortality was registered, and endpoints of mortality were assessed by Kaplan-Meier plots.

Results: The placebo group showed a CRP level of 4.8 ng/mL at the start, and 5.1 ng/mL at the study end. The active supplementation group showed a CRP level of 4.1 ng/mL at the start, and 2.1 ng/mL at the study end. SP-selectin exhibited a level of 56.6 mg/mL at the start in the placebo group and 72.3 mg/mL at the study end, and in the active group the corresponding figures were 55.9 mg/mL and 58.0 mg/mL. A significantly smaller increase was demonstrated through repeated measurements of the two biomarkers in those on active supplementation. Active supplementation showed an effect on the CRP and sP-selectin levels, irrespective of the biomarker levels. Reduced cardiovascular mortality was demonstrated in both those with high and low levels of CRP and sP-selectin in the active supplementation group.

Conclusion: CRP and sP-selectin showed significant changes reflecting effects on inflammation and atherosclerosis in those given selenium and coenzyme Q10 combined. A reduced cardiovascular mortality could be demonstrated in the active group, irrespective of biomarker level. This result should be regarded as hypothesis-generating, and it is hoped it will stimulate more research in the area.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. CONSORT diagram illustrating the design of the study.
Fig 2
Fig 2. Graph illustrating C-reactive protein measurements at study start, after 18 months and at study stop at 48 months in the study population given selenium and coenzyme Q10 combined, or placebo.
Note: Analysis according repeated measures of variance.
Fig 3
Fig 3. Graph illustrating sP-selectin measurements at study start, after 18 months and at study stop at 48 months in the study population given selenium and coenzyme Q10 combined, or placebo.
Note: Analysis according repeated measures of variance.
Fig 4
Fig 4. Distribution of cardiovascular mortality among those with a C-reactive protein concentration below median in those who received active supplementation of selenium and coenzyme Q10 combined versus placebo during follow-up of 5.2 years.
Fig 5
Fig 5. Distribution of cardiovascular mortality among those with a C-reactive protein concentration above median in those who received active supplementation of selenium and coenzyme Q10 combined versus placebo during follow-up of 5.2 years.
Fig 6
Fig 6. Distribution of cardiovascular mortality among those with a sP-selectin concentration below median in those who received active supplementation of selenium and coenzyme Q10 combined versus placebo during follow-up of 5.2 years.
Fig 7
Fig 7. Distribution of cardiovascular mortality among those with a sP-selectin concentration above median in those who received active supplementation of selenium and coenzyme Q10 combined versus placebo followed during 5.2 years.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

References

    1. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5(8):927–46. - PMC - PubMed
    1. Shantsila E, Tapp LD, Lip GY. Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. Int J Cardiol. 2015;185:322–7. 10.1016/j.ijcard.2015.03.105 . - DOI - PubMed
    1. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114(12):1867–79. 10.1161/CIRCRESAHA.114.302699 - DOI - PMC - PubMed
    1. Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M, et al. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail. 2015;21(2):167–77. 10.1016/j.cardfail.2014.11.004 . - DOI - PubMed
    1. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011;57(7):861–9. 10.1016/j.jacc.2010.10.018 . - DOI - PubMed

Publication types

MeSH terms

Grant support

This work was supported by the County Council of Östergötland, Linköping University. The funder had no role in the design, management, analysis, interpretation of the data, preparation, review or approval of the manuscript.
Feedback